Michael M. Lipp
29Patents
11h-index
23Co-inventors
75Inventor score
Filing activity: Aug 25, 1999 → Dec 28, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6586008B1 | Use of simple amino acids to form porous particles during spray drying | Human Necessities | 41 | Expired |
| US7947742B2 | Inhalable epinephrine | Human Necessities | 36 | Active |
| US7182961B2 | Particulate compositions for pulmonary delivery | Human Necessities | 24 | Expired |
| US7384649B2 | Particulate compositions for pulmonary delivery | Human Necessities | 23 | Active |
| US9061352B2 | Dry powder formulations and methods for treating pulmonary diseases | Human Necessities | 15 | Active |
| US7807200B2 | Formulations for spray-drying large porous particles | Human Necessities | 14 | Active |
| US8415397B2 | Inhalable epinephrine | Human Necessities | 14 | Active |
| US7252840B1 | Use of simple amino acids to form porous particles | Human Necessities | 13 | Expired |
| US8758824B2 | Respirably dry powder comprising calcium lactate, sodium chloride and leucine | Emerging Cross-Sectional Technologies | 13 | Active |
| US9333174B2 | Use of simple amino acids to form porous particles | Human Necessities | 12 | Active |
| US8747813B2 | Inhalable epinephrine | Human Necessities | 12 | Active |
| US8614255B2 | Pulmonary pharmaceutical formulations | Human Necessities | 7 | Active |
| US8992983B2 | Respirably dry powder comprising calcium lactate, sodium chloride and leucine | Emerging Cross-Sectional Technologies | 6 | Active |
| US9387169B2 | Rapamycin powders for pulmonary delivery | Human Necessities | 6 | Active |
| US9233158B2 | Dry powder formulations and methods for treating pulmonary diseases | Human Necessities | 6 | Active |
| US9119778B2 | Dry powder formulations and methods for treating pulmonary diseases | Human Necessities | 4 | Active |
| US9744130B2 | Cationic dry powders | Human Necessities | 4 | Active |
| US9238005B2 | Dry powder formulations and methods for treating pulmonary diseases | Human Necessities | 4 | Active |
| US9433576B2 | Cationic dry powders | Human Necessities | 3 | Active |
| US8268358B2 | Use of simple amino acids to form porous particles | Human Necessities | 3 | Active |
| US8945612B2 | Capsules containing high doses of levodopa for pulmonary use | Human Necessities | 3 | Active |
| US9642798B2 | Monovalent metal cation dry powders for inhalation | Chemistry; Metallurgy | 3 | Active |
| US10376465B2 | Monovalent metal cation dry powders for inhalation | Chemistry; Metallurgy | 3 | Active |
| US8545878B1 | Capsules containing high doses of levodopa for pulmonary use | Human Necessities | 3 | Active |
| US9393210B2 | Capsules containing high doses of levodopa for pulmonary use | Human Necessities | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.